56
Views
10
CrossRef citations to date
0
Altmetric
Original Research

The association of HIF-1α expression with clinicopathological significance in prostate cancer: a meta-analysis

, , , &
Pages 2809-2816 | Published online: 21 Aug 2018

Abstract

Background

Hypoxia-inducible factor-1α (HIF-1α) plays an important role in tumor growth, invasion, and metastasis. The aim of this study was to perform a meta-analysis to explore the association of HIF-1α expression with clinicopathological significance in patients with prostate cancer (PCa).

Methods

A detailed literature search was made in PubMed, Embase, Cochrane Library, China Biology Medicine disc (CBM), and China National Knowledge Infrastructure (CNKI) up to August 21, 2017. Odds ratios (ORs) with 95% CIs were calculated to evaluate the strength of the correlations. Analysis of pooled data was performed using Review Manager 5.3 software.

Results

Eventually, 14 studies were identified and involved in this meta-analysis. The rate of HIF-1α protein expression was significantly higher in PCa than in nonmalignant prostate tissues (OR=12.01, 95% CI: 8.22–17.55, P<0.00001). Similar results were found in different subgroups. There were significant differences between HIF-1α expression and clinicopathological significance. The expression of HIF-1α protein was significantly associated with Gleason score (Gleason ≥7 vs Gleason <7: OR=3.58, 95% CI: 2.35–5.46, P<0.00001). The frequency of HIF-1α protein expression was significantly higher in T3–T4 stages than in T1–T2 stages of PCa (OR=3.70, 95% CI: 1.53–8.96, P=0.004). The expression of HIF-1α protein was significantly associated with the presence of lymph node and/or bone metastasis of PCa (metastasis positive vs negative: OR=7.07, 95% CI: 4.08–12.25, P<0.00001).

Conclusion

Taken together, our findings have demonstrated the certain associations of HIF-1α expression with an increased risk and clinicopathological significance in PCa patients, indicating that HIF-1α may serve as a valuable biomarker for diagnosing PCa and monitoring the progression.

Introduction

Prostate cancer (PCa) seriously threatens psychological and physical health worldwide. It remains the most common malignancy diagnosed and the third highest cause of leading cancer-related death in males in the USA. An estimation of 2017 cancer statistics revealed 161,360 new cases and 26,730 newly related deaths assigned to PCa.Citation1 Currently, although there are different treatment options for PCa including surgery, local radiotherapy, castration, and chemotherapy, the molecular mechanisms for the emergence and progression of PCa remain research focus in recent years.Citation2,Citation3 Especially, molecular biomarkers that predict the progression and clinical outcome would allow earlier and more appropriate therapeutic approaches for PCa. Therefore, new progressive and prognostic indicators for PCa are urgently required.

Hypoxia is a reduction in the normal concentration of tissue oxygen which occurs in many diseases including cancer. A key effect of hypoxia is the induction of genetic alterations and angiogenic stimulation, leading to a more aggressive cell phenotype and malignant progression.Citation4 Hypoxia-inducible factor (HIF) is a DNA-binding transcription factor, which responds to hypoxia. Recent advances have pointed to the critical role of HIF-1α in cell development, progression, and the metastasis of PCa.Citation5,Citation6 However, the clinical relevance of the expression of HIF-1α in PCa remains controversial, and the association of HIF-1α expression with clinicopathological features is inconclusive due to the relatively small sample sizes in the included study. Meta-analysis can obtain a relatively precise and accurate estimation through incorporating all available evidences using statistical software.Citation7 Thus, we conducted a meta-analysis to assess the possible correlations between HIF-1α expression and clinicopathological significance in PCa, hoping to provide evidences for exploring molecular mechanisms and some novel potential biomarkers of PCa.

Methods

Ethics statement

No patient’s privacy or clinical samples were involved in this study; hence, ethical approval was not required.

Search strategy

Literature resources including PubMed, Embase, Cochrane Library, CBM, and China National Knowledge Infrastructure (CNKI) were searched for eligible literatures, using the terms (“hypoxia-inducible factor or hypoxia-inducible factor-1 or hypoxia-inducible factor-1α or hypoxia-inducible factor-1A or HIF or HIF-1 or HIF-1α OR HIF-1A”) and (“prostatic cancer” or “prostate cancer” or “prostatic carcinoma” or “prostate carcinoma” or “PCa”). Last search of current investigation was updated on August 21, 2017. Additionally, the publication language was only limited to English and Chinese. In case of omission, we identified the reference lists of relevant articles and review articles to seek for potentially relevant studies. We did not contact the corresponding authors if the relevant data were unavailable.

Inclusion and exclusion criteria

Studies which satisfied the following criteria were included in our study: 1) clinical study about the association of HIF-1α expression with PCa risk, 2) studies which contained relevant available data, and 3) PCa was histologically confirmed. Studies were excluded if they met the following criteria: 1) the available data about associations were absent, 2) similar or duplicate study (when the same or similar cohort was applied, after careful examination, the most complete information was included), 3) other type of article including review or abstract, and 4) studies involving cells lines or animal models.

Data extraction

Based on the inclusion and exclusion criteria, we extracted the relevant information from each eligible publication. Any disagreements were resolved by discussion between authors (Meng Huang and Hexi Du) or reviewed by a third author (Hong Che). The data on first author, publication year, study country, ethnicity, age, sample source, test method, control source, the HIF-1α cutoff value, T stage, Gleason score, TNM stage, lymph node, and/or bone metastasis status were extracted.

Statistical analyses

We explored the association of HIF-1α expression with PCa risk by applying Review Manager software (RevMan 5, The Cochrane Collaboration, Oxford, UK). Odds ratios (ORs) with 95% CIs were calculated for assessing the concrete relationships between HIF-1α expression and PCa risk. Meanwhile, the heterogeneity has been assessed via chi-square-based Q and I2 tests across studies (no heterogeneity ICitation2<25%, moderate heterogeneity ICitation2=25%–50%, and extreme heterogeneity ICitation2>50%).Citation8 In case of extreme heterogeneity (ICitation2>50% or P<0.01 for Q test), we used random-effects (Der-Simonian and Laird method) model.Citation9 Otherwise, fixed-effects (Mantel–Haenszel method) model was introduced.Citation10 One-way sensitivity analyses that individually removed publications in meta-analysis were conducted to assess the stability of the results. It mainly explored the impact of a specific study upon mixed OR. Funnel plots were performed to evaluate the publication bias. P-value <0.05 indicated that there was a bias of study.Citation11

Results

Characteristics of eligible studies

As a result, a total of 14 studies consisting of 1,342 PCa samples satisfied the eligible studies ().Citation12Citation25 Among them, six were written in English and eight were published in Chinese. The principal characteristics of the included studies are summarized in . Of these studies, four studies were involved in two control sources that originated from nonmalignant prostate tissues including normal prostate tissue (NP) and benign prostatic hyperplasia (BPH).Citation12,Citation20,Citation23,Citation24 One study explored the association of HIF-1α expression with lymph node and bone metastasis, respectively.Citation18 We enrolled these independently into the meta-analysis, and this meta-analysis was eventually established based on 19 studies.

Table 1 The characteristics of included studies

Figure 1 Flow diagram of the study selection process in the meta-analysis.

Abbreviations: HIF-1α, hypoxia-inducible factor-1α; PCa, prostate cancer.

Figure 1 Flow diagram of the study selection process in the meta-analysis.Abbreviations: HIF-1α, hypoxia-inducible factor-1α; PCa, prostate cancer.

Quantitative synthesis

Seventeen studies were performed to detect the association between the paired groups. As shown in , the rate of HIF-1α protein expression was significantly higher in PCa than in nonmalignant prostate tissues (OR=12.01, 95% CI: 8.22–17.55, P<0.00001). Additionally, different subgroups analyses regarding country, ethnicity, sample size, and control source were conducted. A similar result was found in different subgroups ().

Table 2 Stratified analysis of HIF-1α protein expression in PCa and nonmalignant prostate tissue

Figure 2 Forest plot for HIF-1α protein expression in PCa and nonmalignant prostate tissue.

Abbreviations: BPH, benign prostatic hyperplasia; HIF-1α, hypoxia-inducible factor-1α; NP, normal prostate tissue; PCa, prostate cancer.

Figure 2 Forest plot for HIF-1α protein expression in PCa and nonmalignant prostate tissue.Abbreviations: BPH, benign prostatic hyperplasia; HIF-1α, hypoxia-inducible factor-1α; NP, normal prostate tissue; PCa, prostate cancer.

In addition, eight, three, six, and two studies were extracted to explore the association of HIF-1α expression with Gleason score, T stage, the presence of metastasis, and TNM stage, respectively. Consequently, the association of HIF-1α expression with clinicopathological significance in PCa was detected. The expression of HIF-1α protein was significantly associated with Gleason score (Gleason ≥7 vs Gleason <7: OR=3.58, 95% CI: 2.35–5.46, P<0.00001) (). The frequency of HIF-1α protein expression was significantly higher in T3–T4 stages than in T1–T2 stages of PCa (OR=3.70, 95% CI: 1.53–8.96, P=0.004) (). The expression of HIF-1α protein was significantly associated with the presence of lymph node and/or bone metastasis of PCa (metastasis positive vs negative: OR=7.07, 95% CI: 4.08–12.25, P<0.00001) (). The expression of HIF-1α protein was significantly associated with TNM stage (III+IV vs I+II: OR=6.85, 95% CI: 2.96–15.87, P<0.001).

Figure 3 Forest plot for HIF-1α protein expression in different Gleason score of PCa.

Abbreviations: HIF-1α, hypoxia-inducible factor-1α; PCa, prostate cancer.

Figure 3 Forest plot for HIF-1α protein expression in different Gleason score of PCa.Abbreviations: HIF-1α, hypoxia-inducible factor-1α; PCa, prostate cancer.

Figure 4 Forest plot for HIF-1α protein expression in different T stage of PCa.

Abbreviations: HIF-1α, hypoxia-inducible factor-1α; PCa, prostate cancer.

Figure 4 Forest plot for HIF-1α protein expression in different T stage of PCa.Abbreviations: HIF-1α, hypoxia-inducible factor-1α; PCa, prostate cancer.

Figure 5 Forest plot for HIF-1α protein expresion in different metastasis status.

Abbreviations: HIF-1α, hypoxia-inducible factor-1α; PCa, prostate cancer.

Figure 5 Forest plot for HIF-1α protein expresion in different metastasis status.Abbreviations: HIF-1α, hypoxia-inducible factor-1α; PCa, prostate cancer.

Sensitivity analysis

Each study was deleted one at a time to assess the specific effect of the individual data on the pooled ORs, and one-way sensitivity analyses suggested that pooled results were relatively stable.

Publication bias evaluation

The funnel plots were largely symmetric (), suggesting there were no publication biases in the meta-analysis of HIF-1α protein expression and clinicopathological features.

Figure 6 Funnel plots for publication bias.

Notes: (A) HIF-1α protein expression in PCa and nonmalignant prostate tissue; (B) HIF-1α protein expression in different Gleason score of PCa; (C) HIF-1α protein expression in different T stage of PCa; and (D) HIF-1α protein expression in different metastasis status.

Abbreviations: HIF-1α, hypoxia-inducible factor-1α; PCa, prostate cancer; OR, odds ratio.

Figure 6 Funnel plots for publication bias.Notes: (A) HIF-1α protein expression in PCa and nonmalignant prostate tissue; (B) HIF-1α protein expression in different Gleason score of PCa; (C) HIF-1α protein expression in different T stage of PCa; and (D) HIF-1α protein expression in different metastasis status.Abbreviations: HIF-1α, hypoxia-inducible factor-1α; PCa, prostate cancer; OR, odds ratio.

Discussion

PCa is one of the most frequent genitourinary malignancies and has become a pivotal cause of male cancer-related deaths worldwide. Particularly, PCa patients often progress to a castration-resistant disease state after receiving initial hormonal therapy over 2–3 years.Citation26,Citation27 Advanced metastatic PCa is accompanied with metastasis to bone, lung, and lymph node. Therefore, the morbidity of PCa has exhibited a sharp increase in recent years. However, the development and progression of PCa remains poorly understood. Therefore, it is particularly important to explore the underlying mechanisms associated with prostate malignant transformation, which efforts should hold great promise in the clinical therapy for PCa. It will also greatly benefit PCa patients who may be utilized in the prediction of PCa outcome and therapeutic efficacy.

Hypoxia is one of the most common conditions that drives development and progression of a variety of disease including cancer. Approximately 60% of the solid tumors exhibit less than 1% O2 concentration in comparison with the adjacent normal tissues. Transient or acute hypoxia occurs in tumors with inadequate blood perfusion, while chronic hypoxia occurs in tumors with limitation of oxygen diffusion.Citation28 The ability of cells to adapt to hypoxia is dependent on a family of HIFs, which induce expression of ~1.0%–1.5% specific target genes.Citation29 The targets of HIF-1 in the glycolytic pathway consist of glucose transporters 1 and 3 (GLUT1 and GLUT3) and enzymes such as hexokinase 2 (HK2) and lactate dehydrogenase A (LDHA), which are also direct targets of the oncogenic MYC transcription factor.Citation30,Citation31 In addition, HIF-1α also induces the secretion of interleukin-6, vascular endothelial growth factor (VEGF), and connective tissue growth factor (CTGF) in cancer- associated fibroblasts (CAFs), which are involved in cancer progression by making contributions to invasion, metastasis, and angiogenesis.Citation32,Citation33 Recently, it has been addressed that HIF-1α could mediate tumor progression through shifting metabolism toward glycolysis, induction of angiogenesis, regulation of apoptosis, induction of migration eventually making cancer cells to escape hostile hypoxic environments, and resist to therapeutics.Citation34,Citation35 A hallmark of the progression of PCa to advanced disease is the acquisition of androgen-independent growth.Citation36 It is well established that PCa under hypoxia often possessed aggressive tumor phenotypes, and even chemotherapy or radiotherapy resistance.Citation37 An effective therapy against PCa under hypoxia is desperately needed. Recent studies presented the inhibitory effects of tocotrienol and its redox-silent analog which could inhibit the survival of PC3 stem-like cells under hypoxia, primarily through the suppression of HIF-1α signaling, and may subsequently establish the newly effective therapeutic approach for androgen-independent PCa.Citation38,Citation39

Recent advances have explored a central role of HIF-1α in PCa development and progression. The investigations that focused on the clinical correlation of HIF-1α with PCa progression were relatively rare and inconclusive, which could be explained by the relatively small sample sizes. Meta-analysis is a useful tool to obtain a relatively precise estimation. As a result, association of HIF-1α expression with PCa clinicopathological significance was explored in current meta-analysis to elucidate the role of HIF-1α in PCa progression. In conclusion, the rate of HIF-1α protein expression in PCa was significantly higher than in nonmalignant prostate tissues. The increased expression of HIF-1α protein was significantly associated with clinicopathological significance for patients suffering from PCa.

Limitations

First, published studies written only in English or Chinese might not provide sufficient evidences which may subsequently result in certain publication bias. Additionally, studies without a consistent HIF-1α cutoff value may influence the ultimate results. Meanwhile, the heterogeneity suggested that potential or undiscovered factors might be ignored. Despite limitations, a certain relationship of HIF-1α expression with PCa clinicopathological significance has been explored in current meta-analysis.

Conclusion

The high expression of HIF-1α protein was significantly associated with clinical diagnostic and clinicopathological significances for patients with PCa. Taken together, our findings have indicated that HIF-1α expression was a potentially diagnostic biomarker of PCa and could potentially be applied for noninvasively monitoring progression of PCa patients in the future.

Acknowledgments

This meta-analysis was supported by grants from the Clinical Key Subjects Program of the Ministry of Public Health (Urology), the National Natural Science Foundation of China (81630019). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Disclosure

The authors report no conflicts of interest in this work.

References

  • SiegelRLMillerKDJemalACancer statistics, 2017CA Cancer J Clin201767173028055103
  • YapTASmithADFerraldeschiRAl-LazikaniBWorkmanPde BonoJSDrug discovery in advanced prostate cancer: translating biology into therapyNat Rev Drug Discov2016151069971827444228
  • ZhaoRWangYZhangMScreening of potential therapy targets for prostate cancer using integrated analysis of two gene expression profilesOncol Lett20171455361536929113170
  • SchitoLSemenzaGLHypoxia-inducible factors: master regulators of cancer progressionTrends Cancer201621275877028741521
  • MakPLiJSamantaSMercurioAMERβ regulation of NF-kB activation in prostate cancer is mediated by HIF-1Oncotarget2015637402474025426450901
  • XiaoLJChenYYLinPHypoxia increases CX3CR1 expression via HIF-1 and NF-κB in androgen-independent prostate cancer cellsInt J Oncol20124151827183622941344
  • MunafoMRFlintJMeta-analysis of genetic association studiesTrends Genet200420943944415313553
  • HigginsJPThompsonSGQuantifying heterogeneity in a meta-analysisStat Med200221111539155812111919
  • DerSimonianRLairdNMeta-analysis in clinical trialsControl Clin Trials1986731771883802833
  • MantelNHaenszelWStatistical aspects of the analysis of data from retrospective studies of diseaseJ Natl Cancer Inst195922471974813655060
  • BeggCBBerlinJAPublication bias and dissemination of clinical researchJ Natl Cancer Inst19898121071152642556
  • WuFDingSLiXElevated expression of HIF-lα in actively growing prostate tissues is associated with clinical features of benign prostatic hyperplasiaOncotarget2016711120531206226919249
  • BaoXZFanGMWuZMExpression and significance of HIF-lα in prostate cancerMod Chin Dr201553713
  • GuoWChenMNHeXLExpression and clinical significance of HIF-l(VEGF and VEGFR-3 in prostate cancerJ Contemp Urol Reproduct Oncol201464231234
  • RanasingheWKXiaoLKovacSThe role of hypoxia-inducible factor 1α in determining the properties of castrate-resistant prostate cancersPLoS One201381e5425123342109
  • LiXHeCHXuCBLiYPExpressions and clinical significances of nuclear factor-κB and hypoxia inducible factor-1α in prostate cancerJ Chongqing Med Univ2013388872875
  • HuangHLuZQDuTThe expression and correlation studies about carbon anhydrase IX (CA-IX) and hypoxia-inducible factor-1 prostate cancerChin J Endourol201265405409
  • LiWZhangHDLiZQYuZGNiuXDLiZQExpression of VEGF and HIF-1α in prostate adenocarcinoma and their significanceMed J Chin Peoples Liberation Army20122451113
  • ShiHQZhaiXLLiuQWExpression and clinical significance of HIF-1α in prostate cancerJ Pract Oncol2007389265267
  • WangLChenZJWangQTExpression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor in prostate cancer and its significanceZhonghua Nan Ke Xue2006121575916483162
  • LekasALazarisACDeliveliotisCThe expression of hypoxia-inducible factor-1 alpha (HIF-1alpha) and angiogenesis markers in hyperplastic and malignant prostate tissueAnticancer Res2006264B2989299316886625
  • PingHChenXCWangHChenCHZengFCLuGCExpression and significance of HIF-lα in prostate cancerChin J Urol20042528890
  • ZhongHSemenzaGLSimonsJWDe MarzoAMUp-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesisCancer Detect Prev2004282889315068831
  • DuZFujiyamaCChenYMasakiZExpression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissueChin Med J (Engl)2003116121936193914687488
  • ZhongHDe MarzoAMLaughnerEOverexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastasesCancer Res199959225830583510582706
  • TeitelbaumAHBuiCNSpaldingJRTreatment patterns of castration-resistant prostate cancer: a retrospective claims database analysisJ Clin Oncol20123034_suppl198
  • RovielloGCoronaSPBonettaACappellettiMRGeneraliDCirculating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancerOnco Targets Ther2017103811381528814879
  • VaupelPMayerAHypoxia in tumors: pathogenesis-related classification, characterization of hypoxia subtypes, and associated biological and clinical implicationsAdv Exp Med Biol2014812812192424729210
  • SemenzaGLOxygen sensing, hypoxia-inducible factors and disease pathophysiologyAnnu Rev Pathol201491477123937437
  • ChristofkHRVander HeidenMGHarrisMHThe M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumor growthNature2008452718423023318337823
  • DangCVKimJWGaoPYusteinJThe interplay between MYC and HIF in cancerNat Rev Cancer200881515618046334
  • De FrancescoEMLappanoRSantollaMFMarsicoSCarusoAMaggioliniMHIF-1a/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs)Breast Cancer Res2013154R6423947803
  • RenJGuoHWuHGPER in CAFs regulates hypoxia-driven breast cancer invasion in a CTGF-dependent mannerOncol Rep20153341929193725647524
  • KarakashevSVReginatoMJProgress toward overcoming hypoxia-induced resistance to solid tumor therapyCancer Manag Res2015725326426316817
  • LuoDWangZWuJJiangCWuJThe role of hypoxia inducible factor-1 in hepatocellular carcinomaBiomed Res Int201420143–440927225101278
  • ZhangWMengYLiuNWenXFYangTInsights into chemoresistance of prostate cancerInt J Biol Sci201511101160117026327810
  • HarrisALHypoxia – a key regulatory factor in tumour growthNat Rev Cancer200221384711902584
  • KanekoSSatoCShiozawaNSuppressive effect of delta-tocotrienol on hypoxia adaptation of prostate cancer stem-like cellsAnticancer Res20183831391139929491063
  • ShiozawaNSugaharaRNamikiKInhibitory effect of a redox-silent analogue of tocotrienol on hypoxia adaptation in prostate cancer cellsAnticancer Drugs201728328929727926612